Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-078730
Filing Date
2025-08-14
Accepted
2025-08-14 16:48:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11646
  Complete submission text file 0001104659-25-078730.txt   13481
Mailing Address 475 SANSOME STREET SUITE 1720 SAN FRANCISCO CA 94111
Business Address 475 SANSOME STREET SUITE 1720 SAN FRANCISCO CA 94111 415-281-1022
PFM Health Sciences, LP (Filed by) CIK: 0001442756 (see all company filings)

EIN.: 262000428 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Subject) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92515 | Film No.: 251220424
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)